28/11/2014 15:33:17 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
11/26/201411:34AMBWBristol-Myers Squibb Receives Complete Response Letter from U.S. Food & Drug Administration for Daclatasvir, an Investigation...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C (HCV). The initial daclatasvir... More...>>
11/24/20149:57AMDJNBristol-Myers, Five Prime to Collaborate on Immunotherapy
By Tess Stynes Bristol-Myers Squibb Co. (BMY) and Five Prime Therapeutics Inc. (FPRX) agreed to collaborate on potential combinations of their investigational immunotherapies to treat six types of cancers. Five Prime shares rose 14.3% to $18 in recent premarket trading. Immunotherapy drugs work by unleashing the body's... More...>>
11/24/20148:59AMBWBristol-Myers Squibb & Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Inves...
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed... More...>>
11/19/20145:59AMPRNCAOpdivo (nivolumab), un nouvel inhibiteur du point de contrôle immunitaire PD-1, est le premier à avoir produit un bienfait ...
Opdivo (nivolumab), un nouvel inhibiteur du point de contrôle immunitaire PD-1, est le premier à avoir produit un bienfait sur le plan de la survie lors d'un essai de phase III sur le mélanome au stade avancé jamais traité Canada NewsWire MONTRÉAL, le 19 nov. 2014 Les résultats de l'étude... More...>>
11/19/20145:59AMPRNCANew PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment n...
New PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment naïve advanced melanoma Canada NewsWire MONTREAL, Nov. 19, 2014 Results of study conducted in Canada, Australia and Europe presented at Society for Melanoma Research and published in The New... More...>>
11/18/20142:00AMBWAllied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Inn...
Synergy Partners offers significant experience in drug discovery and development. Areas of specialty include R&D strategy, medicinal chemistry, pharmacology, metabolism, drug safety and clinical development. Synergy Partners will provide strategic advice and scientific support to Allied-Bristol Life Sciences’ R&D... More...>>
11/17/20148:00AMBWAnalyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citru...
First-line therapy with Orencia in combination with MTX resulted in patients with early RA achieving significantly higher rates of stringent measures of remission, including 37 percent of patients achieving Boolean-defined remission and 42 percent of patients achieving CDAI- and SDAI-defined remission at 12 months versus... More...>>
11/16/20143:45AMBWStudy Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Che...
Opdivo demonstrated superior overall survival vs. dacarbazine with a one-year survival rate of 73% vs. 42% and a 58% decrease in the risk of death (Hazard Ratio [HR] = 0.42, P<0.0001) Objective response rate was significantly higher for Opdivo than dacarbazine (40% vs.14%), including a higher percentage of complete... More...>>
11/14/20146:00AMBWBristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland
State-of-the-art facility will produce multiple therapies for the company’s growing biologics portfolio Significant investment builds on 50 years of company’s manufacturing history in Ireland 350 to 400 manufacturing jobs and about 1,000 construction jobs expected to be created Bristol-Myers Squibb Company (NYSE:BMY... More...>>
11/13/20145:59AMPRNCABristol-Myers Squibb annonce des taux élevés de guérison chez les patients atteints d'hépatite C de génotype 3 avec le t...
Bristol-Myers Squibb annonce des taux élevés de guérison chez les patients atteints d'hépatite C de génotype 3 avec le traitement associant le daclatasvir au sofosbuvir au cours de l'essai ALLY-3 Canada NewsWire MONTRÉAL, le 13 nov. 2014 Avec le premier schéma thérapeutique à prise orale... More...>>
11/13/20145:59AMPRNCAUne nouvelle étude menée notamment dans 10 centres de recherche canadiens montre des taux de guérison élevés chez les pa...
Une nouvelle étude menée notamment dans 10 centres de recherche canadiens montre des taux de guérison élevés chez les patients atteints d'hépatite C de génotype 1 traités par la nouvelle trithérapie à dose fixe et à prise orale à base de daclatasvir de Bristol-Myers... More...>>
11/13/20145:59AMPRNCANew study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squib...
New study involving 10 canadian research sites shows high cure rates for genotype 1 hepatitis C using new Bristol-Myers Squibb all-oral daclatasvir TRIO fixed-dose combination Canada NewsWire MONTREAL, Nov. 13, 2014 All-oral, 12-week treatment in UNITY-2 trial achieves 98% cure rate in treatment-naïve and 93% in treatment-experienced... More...>>
11/13/20145:59AMPRNCABristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ...
Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial Canada NewsWire MONTREAL, Nov. 13, 2014 Sustained virologic response after 12 weeks achieved in 90% of treatment-naïve and 86% of treatment-experienced patients in first all-oral, ribavirin-free... More...>>
11/12/20148:36AMBWBristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014...
First U.S. presentation of clinical and imaging results from Phase IIIb trial evaluating treatment with Orencia plus Methotrexate (MTX) combination therapy in patients positive for anti-citrullinated protein (anti-CCP) antibodies with early moderate to severe rheumatoid arthritis (RA) Real-world data highlighting meaningful... More...>>
11/11/20147:48AMPRNUSBristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel...
Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel Ways to Cure Viral Diseases PR Newswire PARIS, November 11, 2014 PARIS, November 11, 2014 /PRNewswire/ -- The Partnering for Cure faculty of experts today announced the four recipients of awards... More...>>
11/11/20147:48AMPRNUSBristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel...
Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel Ways to Cure Viral Diseases PR Newswire PARIS, November 11, 2014 PARIS, November 11, 2014 /PRNewswire/ -- The Partnering for Cure faculty of experts today announced the four recipients of awards... More...>>
11/10/20149:00AMBWBristol-Myers Squibb Foundation Awards $2 Million in New Grants to Help Veterans & their Families Transition from Military to...
Sesame Workshop, The Mission Continues and Tragedy Assistance Programs for Survivors receive support to provide innovative community-based solutions for veterans, military families and caregivers As America prepares to salute the nation’s military veterans for their service and sacrifice, the Bristol-Myers Squibb Foundation... More...>>
11/08/20149:00AMBWPhase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Gen...
Daclatasvir TRIO achieves 98% cure rate in treatment-naïve and 93% cure rate in treatment-experienced genotype 1 patients with cirrhosis when used with ribavirin, as shown in UNITY 2 12-week, all-oral treatment halves current regimen duration for hard-to-manage treatment-experienced genotype 1 patients with cirrhosis... More...>>
11/08/20149:00AMBWALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir & Sofosbuvir Combination among Genotype 3 Hepatitis C...
Daclatasvir+sofosbuvir regimen achieves SVR12 in 90% of treatment-naïve and 86% of treatment-experienced genotype 3 patients ALLY-3 is the first Phase 3 study of an all-oral, ribavirin-free treatment regimen for genotype 3 HCV patients with a 12-week treatment duration Genotype 3 is the second most common genotype worldwide... More...>>
11/07/20141:44PMBWMultiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hem...
Study results from investigational agents Opdivo (nivolumab), elotuzumab, and ulocuplumab, as well as Sprycel (dasatinib), will be highlighted First presentation of data for Opdivo in Hodgkin lymphoma and non-Hodgkin lymphoma, and final Phase 2 results of elotuzumab in multiple myeloma highlight potential of immuno-oncology... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy141128 15:33